BTC$65,739.00-0.43%
ETH$1,928.41-0.08%
USDT$0.9994+0.02%
BNB$569.73-0.23%
USDC$0.99990.00%
XRP$1.13-0.23%
SOL$77.70+0.11%
TRX$0.3278-0.67%
FIGR_HELOC$1.00-0.33%
HYPE$59.09-0.07%
DOGE$0.0724-0.38%
RAIN$0.0144-2.14%
USDS$0.9999+0.00%
LEO$9.73+0.06%
ZEC$514.65-0.40%
WBT$57.45-0.13%
BTC$65,739.00-0.43%
ETH$1,928.41-0.08%
USDT$0.9994+0.02%
BNB$569.73-0.23%
USDC$0.99990.00%
XRP$1.13-0.23%
SOL$77.70+0.11%
TRX$0.3278-0.67%
FIGR_HELOC$1.00-0.33%
HYPE$59.09-0.07%
DOGE$0.0724-0.38%
RAIN$0.0144-2.14%
USDS$0.9999+0.00%
LEO$9.73+0.06%
ZEC$514.65-0.40%
WBT$57.45-0.13%
Danaher stock fell after the company announced a $9.9B all-cash deal to buy Masimo, expanding its diagnostics and patient monitoring business.
Danaher Corporation has outperformed market expectations in Q4 2025, reporting an EPS of $2.23 and revenue of $6.84 billion, both exceeding anticipated figures.
Danaher reported Q3 revenue of $6.1 billion and EPS of $1.89, topping estimates and maintaining a positive full-year outlook.
Danaher Corporation's second quarter results for 2025 show a notable increase in revenue and net earnings, exceeding analyst expectations.
Danaher Corporation (NYSE: DHR) reported strong Q3 results with net earnings of $818 million.
Danaher Corporation reported solid financial results for the Q2 2024, with net earnings of $907 million and revenues totaling $5.7 billion.
Danaher Corporation exceeded market expectations in Q1 2024, reporting net earnings of $1.1 billion and non-GAAP diluted net earnings per common share of $1.92.
Danaher Corporation announced strong Q4 results, outperforming expectations.